A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

Purpose BI 831266 is a potent, selective, low-molecular-weight inhibitor of Aurora kinase B. This trial aimed to determine the maximum tolerated dose (MTD) of BI 831266 in patients with advanced solid tumors (NCT00756223; EudraCT 2008-001631-36; 1257.1). Methods BI 831266 (4–130 mg) was administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Dittrich, Christian, Fridrik, Michael A., Koenigsberg, Robert, Lee, Chooi, Goeldner, Rainer-Georg, Hilbert, James, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387274/
https://www.ncbi.nlm.nih.gov/pubmed/25529193
http://dx.doi.org/10.1007/s10637-014-0201-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387274/
https://www.ncbi.nlm.nih.gov/pubmed/25529193
http://dx.doi.org/10.1007/s10637-014-0201-7

Ejemplares similares